MARKET

MYMD

MYMD

MyMD Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.640
+0.150
+4.30%
After Hours: 3.640 0 0.00% 16:42 05/18 EDT
OPEN
3.500
PREV CLOSE
3.490
HIGH
3.800
LOW
3.400
VOLUME
147.47K
TURNOVER
--
52 WEEK HIGH
13.94
52 WEEK LOW
3.300
MARKET CAP
30.31M
P/E (TTM)
-1.1465
1D
5D
1M
3M
1Y
5Y
BRIEF-MyMD Appoints David Rini To Scientific Advisory Board
reuters.com · 1d ago
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Adv...
BusinessWire · 1d ago
Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting
Check out the full agenda via Benzinga's Events page:  * the list below is limited to some of the publicly-traded companies that will be presenting · 5d ago
Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX
Today's 5 Stock Ideas (BZ Small Cap Event Edition) Benzinga is hosting another of it's famed Benzinga Global Small Cap Conferences this week!  The festivities kick off Thursday morning just after 9 a.m.
Benzinga · 5d ago
MyMD Pharmaceuticals Schedules Business Update Conference Call
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced it will host a conference call at 4:15 p.m. Eastern time on Monday, Ma...
BusinessWire · 6d ago
MyMD Pharmaceuticals: Invitation to the Benzinga Global Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - May 10, 2021) - MyMD Pharmaceuticals (NASDAQ: MYMD) will be presenting at the Benzinga Global Small Cap Conference taking place on May 13-14, 2021. We invite our shareholders and all interested parties to explore invest...
Newsfile · 05/10 13:00
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Med...
Business Wire · 04/28 15:13
MyMD Pharmaceuticals Announces Issuance Of Allowance From United States Patent And Trademark Office For Synthetic Cannabinoid Compounds
Patent protects Supera-CBD, a preclinical cannabidiol derivative that targets cannabinoid receptor type 2 for the treatment of neuroinflammatory and neurodegenerative diseases. MyMD Pharmaceuticals,
Benzinga · 04/22 13:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYMD. Analyze the recent business situations of MyMD Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYMD stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 790.95K
% Owned: 9.50%
Shares Outstanding: 8.33M
TypeInstitutionsShares
Increased
7
192.57K
New
6
26.01K
Decreased
0
0
Sold Out
2
17.18K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.39%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/Director
Joshua Silverman
Chief Executive Officer/Director
.. Gormally
President/Director
Chris Chapman
Chief Financial Officer
Ian Rhodes
Executive Vice President/General Counsel
Paul Rivard
Chief Scientific Officer
Adam Kaplin
Director
Craig Eagle
Director
Jude Uzonwanne
Independent Director
Robert Schroeder
Independent Director
Bill White
No Data
About MYMD
MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Webull offers kinds of MyMD Pharmaceuticals Inc stock information, including NASDAQ:MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.